RETEVMO
PeakNDAORALCAPSULEPriority Review
Approved
May 2020
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 15h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RETEVMO (selpercatinib) is an oral, small-molecule RET kinase inhibitor approved in May 2020 for RET-driven cancers including medullary thyroid carcinoma and RET-fusion positive non-small cell lung cancer. It selectively blocks the Rearranged during Transfection (RET) protein, which drives oncogenic signaling in patients with specific genetic mutations.
$58MPart D
Growth12.4 years to LOEEarly-stage commercial trajectory with modest Part D spend of $58M (2023) suggests an emerging franchise with room for market expansion and growing team investment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on RETEVMO offers exposure to precision oncology, Eli Lilly's oncology franchise expansion, and a product in its growth phase with 12+ years of patent runway. Career growth potential is moderate to high due to nascent commercial opportunity and long exclusivity window, though competition from established kinase inhibitors may limit ceiling.
Brand ManagerMedical Science Liaison (MSL)
Worked on RETEVMO at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.